Vectorious Medical Technologies Completes $5M Raise

TEL-AVIV, Israel, February 26, 2015 /PRNewswire/ --

- Company Continuing to Develop its Groundbreaking CHF (Congestive Heart Failure) Monitoring System Toward 1^st-In-Man Trial -  

Vectorious Medical Technologies, an Israeli company developing a novel cardiac monitoring system for patients suffering from congestive heart failure (CHF), announced today that it has closed a $5 million financing round. Investors in the round included the RadBioMed incubator, which is owned jointly by Yehuda Zisapel and Prof. Nava Zisapel; several private investors, including Zohar Gilon, Gur Muntzer and others; and the U.S.-based Global Cardiovascular Innovation Center (GCIC) of the Cleveland Clinic. Vectorious will use the proceeds for further development as needed to initiate first in-human trials in collaboration with senior cardiologists from America and Israel.

"We are gratified to close this major financing round, a vote of confidence that these strategic investors  have made for our groundbreaking CHF management approach," commented Oren Goldstein, Vectorious's founder and CEO. "Our solution will make daily monitoring a routine activity for CHF patients and their physicians, similar to glucose monitoring for diabetes patients. This will lead to reduced CHF morbidities and readmissions, a higher quality-of-life for CHF patients, and huge financial savings to the health system."

Vectorious Medical Technologies Ltd. is a privately-held Israeli medical device company developing a novel monitoring system for CHF patients based on a miniature wireless implant to enable daily "push button" readings of left atrial pressure, a platform that will enable a significant improvement in the management of congestive heart failure (CHF). The system implements a novel approach to long-term, implant-based hemodynamic monitoring that leverages state-of-the-art technologies in the areas of miniature sensing and wireless communications.

Market acceptance of the implantable hemodynamic monitoring approach to CHF management has been paved by the May 2014 FDA approval for commercial use of the CardioMEMS wireless implant device for monitoring patients with heart failure. The Company believes, however, that Vectorious's differentiated monitoring approach, which is based on the measurement of left atrial pressure, provides an earlier and more specific cardiac indication than does the CardioMEMS device, which measures pulmonary artery pressure.

For more information, please refer to Vectorious's internet site at

http://www.vectoriousmedtech.com

For media Contact:
Tel: +972-3-644-7330
Email: info@vectoriousmedtech.com